Pulmonary medication adherence and health-care use in cystic fibrosis

Chest

Volumn 146, Issue 1, 2014, Pages 142-151

  Quittner, Alexandra L ^a   Zhang, Jie ^b   Marynchenko, Maryna ^c   Chopra, Pooja A ^c   Signorovitch, James ^c   Yushkina, Yana ^c   Riekert, Kristin A ^d  

^a Department of Biology   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ANALYSIS GROUP   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; AZTREONAM; COLISTIN; DORNASE ALFA; SODIUM CHLORIDE; TOBRAMYCIN;

ADOLESCENT; ADULT; CHILD; COHORT ANALYSIS; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; DELIVERY OF HEALTH CARE; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MEDICATION ADHERENCE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84903298392     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-1926     Document Type: Conference Paper

References (31)

1. Cystic Fibrosis Foundation Patient Registry. 2011 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2012.
2. Sawicki GS, Ren CL, Konstan MW, Millar SJ, Pasta DJ, Quittner AL; Investigators and Coordinators of the Epide miologic Study of Cystic Fibrosis. Treatment complexity in cystic fi brosis: trends over time and associations with site-specifi c outcomes. J Cyst Fibros. 2013; 12 (5): 461-467.
3. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al; Pulmo nary Clinical Practice Guidelines Committee. Cystic fi brosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013; 187 (7): 680-689.
4. Pressler T, Henig NR, Malyszczak W. Aztreonam for inhalation solution, an aerosolized antibiotic for the treatment of pseudomonal airway infection in patients with cystic fi brosis. U S Res Dis. 2011; 7 (2): 107-112.
5. Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Riekert KA. Longitudinal association between medication adherence and lung health in people with cystic fi brosis. J Cyst Fibros. 2011; 10 (4): 258-264.
6. Sawicki GS, Rasouliyan L, McMullen AH, et al. Longitudinal assessment of healthrelated quality of life in an observational cohort of patients with cystic fi brosis. Pediatr Pulmonol. 2011; 46 (1): 36-44.
7. Burrows JA, Bunting JP, Masel PJ, Bell SC. Nebulised dornase alpha: adherence in adults with cystic fi brosis. J Cyst Fibros. 2002; 1 (4): 255-259.
8. Elkins MR, Robinson M, Rose BR, et al; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fi brosis. N Engl J Med. 2006; 354 (3): 229-240.
9. Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL. A multimethod assessment of treatment adherence for children with cystic fi brosis. J Cyst Fibros. 2006; 5 (3): 177-185.
10. Quinn J, Latchford G, Duff A, Conner M, Pollard K, Morrison L. Measuring, predicting and improving adherence to inhala tion in patients with CF: a randomised controlled study of motivational interviewing [abstract]. Pediatr Pulmonol. 2004; 38 (S27): 360.
11. Modi AC, Quittner AL. Utilizing computerized phone diary procedures to assess health behaviors in family and social contexts. Child Health Care. 2006; 35 (1): 29-45.
12. Zindani GN, Streetman DD, Streetman DS, Nasr SZ. Adher ence to treatment in children and adolescent patients with cystic fi brosis. J Adolesc Health. 2006; 38 (1): 13-17.
13. Smith BA, Modi AC, Quittner AL, Wood BL. Depressive symptoms in children with cystic fi brosis and parents and its eff ects on adherence to airway clearance. Pediatr Pulmonol. 2010; 45 (8): 756-763.
14. Modi AC, Cassedy AE, Quittner AL, et al. Trajectories of adherence to airway clearance therapy for patients with cystic fi brosis. J Pediatr Psychol. 2010; 35 (9): 1028-1037.
15. Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell LM. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med. 2011;11:5.
16. Wertz DA, Chang CL, Stephenson JJ, Zhang J, Kuhn RJ. Economic impact of tobramycin in patients with cystic fi brosis in a managed care population. J Media Econ. 2011; 14 (6): 759-768.
17. Nasr SZ, Chou W, Villa KF, Chang E, Broder MS. Adherence to dornase alfa treatment among commercially insured patients with cystic fi brosis. J Media Econ. 2013;16(6):801-808.
18. Hansen LG, Chang S. White Paper: Health Research Data for the Real World: The MarketScan Databases. Ann Arbor, MI: Truven Health Analytics; 2012.
19. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a metaanalysis. Med Care. 2002; 40 (9): 794-811.
20. Fitzgerald D. Non-compliance in adolescents with chronic lung disease: causative factors and practical approach. Paediatr Respir Rev. 2001; 2 (3): 260-267.
21. Modi AC, Marciel KK, Slater SK, Drotar D, Quittner AL. The infl uence of parental supervision on medical adherence in adolescents with cystic fi brosis: developmental shift s from pre to late adolescence. Child Health Care. 2008; 37 (1): 78-92.
22. George M, Rand-Giovannetti D, Eakin MN, Borrelli B, Zettler M, Riekert KA. Perceptions of barriers and facilitators: self-management decisions by older adolescents and adults with CF. J Cyst Fibros. 2010; 9 (6): 425-432.
23. Eaddy MT, Cook CL, O'Day K, Burch SP, Cantrell CR. How patient cost-sharing trends aff ect adherence and outcomes: a literature review. P T. 2012;37(1):45-55.
24. Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fi brosis and asthma: what gets in the way? J Pediatr Psychol. 2006; 31 (8): 846-858.
25. Abbott J, Havermans T, Hart A. Adherence to the medical regimen: clinical implications of new fi ndings. C urr Opin Pulm Med. 2009; 15 (6): 597-603.
26. Riekert KA, Bartlett SJ, Boyle MP, Krishnan JA, Rand CS. The association between depression, lung function, and health-related quality of life among adults with cystic fi brosis. C hest. 2007; 132 (1): 231-237.
27. Goldbeck L, Besier T, Hinz A, Singer S, Quittner AL; TIDES Group. Prevalence of symptoms of anxiety and depression in German patients with cystic fi brosis. Chest. 2010; 138 (4): 929-936.
28. Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009; 47 (8): 826-834.
29. Kahana S, Drotar D, Frazier TJ. Metaanalysis of psychological interventions to promote adherence to treatment in pediatric chronic health conditions. J Pediatr Psychol. 2008; 33 (6): 590-611.
30. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientifi c review. JAMA. 2002; 288 (22): 2868-2879.
31. Ball R, Southern KW, McCormack P, Duff AJ, Brownlee KG, McNamara PS. Adherence to nebulised therapies in adolescents with cystic fi brosis is best on week-days during school term-time. J Cyst Fibros. 2013; 12 (5): 440-444.